SCHEMBL17320558

SCHEMBL17320558

CCNc1cccc(N2CCOCC2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 2/20 0.49
MEF2D Q14814 2/20 0.49
AGXT P21549 1/20 0.49
LMNA P02545 1/20 0.49
PIM1 P11309 1/20 0.48
KMO O15229 1/20 0.48
HDAC3 O15379 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
TTBK1 Q5TCY1 1/20 0.46
TTBK2 Q6IQ55 1/20 0.46
POLB P06746 2/20 0.46
SETD2 Q9BYW2 2/20 0.46
PLOD2 O00469 2/20 0.45
PLOD3 O60568 2/20 0.45
PLOD1 Q02809 2/20 0.45
NPC1 O15118 1/20 0.44
GAA P10253 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28756272 0.84 AGXT (0.52) HDAC4MEF2DAGXTLMNAPIM1
SCHEMBL13996557 0.83 ADRA2C (0.56) AGXTPLOD2PLOD3PLOD1L3MBTL1
SCHEMBL108137 0.82 LMNA (0.53) AGXTLMNAPIM1KMOHDAC3
SCHEMBL3089631 0.82 VSIR (0.52) HDAC4MEF2DAGXTLMNAPIM1
SCHEMBL6992776 0.82 LMNA (0.57) HDAC4MEF2DAGXTLMNAPIM1
SCHEMBL4368142 0.82 GAA (0.62) LMNAPOLBNPC1GAARAB9A
SCHEMBL21966131 0.81 LMNA (0.49) HDAC4MEF2DAGXTLMNAPIM1
SCHEMBL8985943 0.81 ADRB1 (0.57) HDAC4MEF2DMAPT
SCHEMBL1964227 0.81 HDAC4 (0.60) HDAC4MEF2DAGXTLMNAPIM1
Hydrochloric Acid SCHEMBL2470828 0.81 VSIR (0.51) HDAC4MEF2DAGXTLMNAPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230142654-A1 NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF PIMEDBIO, INC. (KR) 2023-05-11 US disclosed
WO-2015187684-A1 TANK-BINDING KINASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2015-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230142654-A1 NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF TYR, TYRO3, TH HDAC4 3311/4885MEF2D 968/4885AGXT 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.